Bioresorbable vascular scaffold implantation in acute coronary syndromes: Clinical evidence, tips and tricks

Postepy w Kardiologii Interwencyjnej

Volumn 11, Issue 3, 2015, Pages 161-169

  Giacchi, Giuseppe ^a   Ortega Paz, Luis ^a   Brugaletta, Salvatore ^a   Ishida, Kohki ^a   Sabaté, Manel ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Acute coronary syndrome; Bioresorbable vascular scaffold; Percutaneous coronary intervention; ST segment elevation myocardial infarction

Indexed keywords

ACUTE CORONARY SYNDROME; BIORESORBABLE SCAFFOLD; BIORESORBABLE VASCULAR SCAFFOLD; CLINICAL TRIAL (TOPIC); DEVICE MAINTENANCE; DEVICE SAFETY; FOLLOW UP; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HUMAN; INTRAVASCULAR ULTRASOUND; OPTICAL COHERENCE TOMOGRAPHY; REGISTER; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBECTOMY; THROMBOSIS; VASOCONSTRICTION;

EID: 84945201161     PISSN: 17349338     EISSN: 18974295     Source Type: Journal    
DOI: 10.5114/pwki.2015.54006     Document Type: Review

References (43)

1. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio- Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-619.
2. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 2012; 33: 16b-25b.
3. Hong MK, Mintz GS, Lee CW, et al. Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation. Circulation 2004; 109: 881-6.
4. Hong MK, Mintz GS, Lee CW, et al. Late stent malapposition after drug-eluting stent implantation: An intravascular ultrasound analysis with long-term follow-up. Circulation 2006; 113: 414-9.
5. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus- eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): A prospective open-label trial. Lancet 2008; 371: 899-907.
6. Scalone G, Brugaletta S, Gómez-Monterrosas O, et al. Bioresorbable scaffolds: focus on vascular response and long-term safety. Panminerva Med 2015; 57: 1-13.
7. Brugaletta S, Radu MD, Garcia-Garcia HM, et al. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis 2012; 22: 106-12.
8. Karanasos A, Simsek C, Gnanadesigan M, et al. OCT assessment of the long-term vascular healing response 5 years after everolimus- eluting bioresorbable vascular scaffold. J Am Coll Cardiol 2014; 64: 2343-56.
9. Brugaletta S, Heo JH, Garcia-Garcia HM, et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur Heart J 2012; 33: 1325-33.
10. Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus- eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): An interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2015; 385: 43-54.
11. Scalone G, Brugaletta S, Gómez-Monterrosas O, et al. ST-segment elevation myocardial infarction - ideal scenario for bioresorbable vascular scaffold implantation? Circ J 2015; 79: 263-70.
12. Kajiya T, Liang M, Sharma RK, et al. Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). EuroIntervention 2013; 9: 501-4.
13. Gori T, Schulz E, Hink U, et al. Early outcome after implantation of absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention 2014; 9: 1036-41.
14. Diletti R, Karanasos A, Muramatsu T, et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J 2014; 35: 777-86.
15. Wiebe J, Möllmann H, Most A, et al. Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Clin Res Cardiol 2014; 103: 141-8.
16. Kochman J, Tomaniak M, Pietrasik A, et al. Bioresorbable everolimus- eluting vascular scaffold in patients with ST-segment elevation myocardial infarction: optical coherence tomography evaluation and clinical outcomes. Cardiol J 2014. doi:10.5603/CJ.a2014.0090. [Epub ahead of print].
17. Gori T, Schulz E, Hink U, et al. Clinical, angiographic, functional, and imaging outcomes 12 months after implantation of drug-eluting bioresorbable vascular scaffolds in acute coronary syndromes. JACC Cardiovasc Interv 2015; 8: 770-7.
18. Rzeszutko Ł, Siudak Z, Włodarczak A, et al. Use of bioresorbable vascular scaffolds in patients with stable angina and acute coronary syndromes. Polish National Registry. Kardiol Pol 2014; 72: 1394-9.
19. Dudek D, Rzeszutko Ł, Zasada W, et al. Bioresorbable vascular scaffolds in patients with acute coronary syndromes: The POLAR ACS study. Pol Arch Med Wewn 2014; 124: 669-77.
20. Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2014. pii: 20140707-06. doi:10.4244/EIJY14M07-11 [Epub ahead of print].
21. Kraak RP, Hassell ME, Grundeken MJ, et al. Initial experience and clinical evaluation of the absorb bioresorbable vascular scaffold (BVS) in real-world practice: The AMC Single Centre Real World PCI Registry. EuroIntervention 2014. pii: 20140316-04. doi:10.4244/EIJY14M08-08. [Epub ahead of print].
22. Wöhrle J, Naber C, Schmitz T, et al. Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds. EuroIntervention 2014. pii: 20140906-04. doi:10.4244/EIJY14M12-10 [Epub ahead of print].
23. Kočka V, Malý M, Toušek P, et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: A prospective multicentre study 'Prague 19'. Eur Heart J 2014; 35: 787-94.
24. Ielasi A, Cortese B, Varricchio A, et al. Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: insights from the multicentre "Registro ABSORB Italiano" (RAI registry). EuroIntervention 2014. pii: 20140629-04. doi:10.4244/EIJY14M10-11 [Epub ahead of print].
25. Brugaletta S, Gori T, Low AF, et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: The BVS-EXAMINATION Study (Bioresorbable Vascular Scaffold-A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction). JACC Cardiovasc Interv 2015; 8: 189-97.
26. Puricel S, Arroyo D, Corpataux N, et al. Comparison of everolimus- And biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol 2015; 65: 791-801.
27. Tamburino C, Latib A, van Geuns RJ, et al. Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: A European perspective. EuroIntervention 2015; 11: 45-52.
28. Brown AJ, McCormick LM, Braganza DM, et al. Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation. Catheter Cardiovasc Interv 2014; 84: 37-45.
29. Mattesini A, Secco GG, Dall'Ara G, et al. ABSORB biodegradable stents versus second-generation metal stents: A comparison study of 100 complex lesions treated under OCT guidance. JACC Cardiovasc Interv 2014; 7: 741-50.
30. Fernández-Rodríguez D, Brugaletta S, Otsuki S, et al. Acute absorb bioresorbable vascular scaffold thrombosis in ST-segment elevation myocardial infarction: To stent or not to stent? EuroIntervention 2014; 10: 600.
31. Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011; 123: 1400-9.
32. Otsuka F, Pacheco E, Perkins LE, et al. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt- chromium XIENCE V stent in a porcine coronary artery model. Circ Cardiovasc Interv 2014; 7: 330-42.
33. Kirtane AJ, Stone GW. How to minimize stent thrombosis. Circulation 2011; 124: 1283-7.
34. Brown AJ, McCormick LM, Braganza DM, et al. Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation. Catheter Cardiovasc Interv 2014; 84: 37-45.
35. Jolly SS, Cairns JA, Yusuf S, et al.; TOTAL Investigators. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 2015 Mar 16 [Epub ahead of print].
36. Valgimigli M, Campo G, Monti M, et al.; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial. Circulation 2012; 125: 2015-26.
37. Valgimigli M, Patialiakas A, Thury A, et al.; ZEUS Investigators. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol 2015; 65: 805-15.
38. Ishibashi Y, Onuma Y, Muramatsu T, et al.; ABSORB EXTEND Investigators. Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial. EuroIntervention 2014; 10: 449-57.
39. Wiebe J, Nef HM, Hamm CW. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J Am Coll Cardiol 2014; 64: 2541-51.
40. Verheye S, Ormiston JA, Stewart J, et al. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- And 12-month clinical and multimodality imaging results. JACC Cardiovasc Interv 2014; 7: 89-99.
41. Ormiston JA, Webber B, Ubod B, et al. An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8/Xpedition). EuroIntervention 2015 Feb 16. pii: 20141214-03. doi:10.4244/EIJY15M02-03 [Epub ahead of print].
42. DESolve ® X-Pand Global Post Market Registry. Data from Clinical Trials. gov: https://clinicaltrials.gov/ct2/show/study/NCT02453035?term=elixir+coronary&rank=6.
43. Everaert B, Felix C, Koolen J, et al. Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: A recommendation from experienced users: A position statement on the use of bioresorbable vascular scaffolds in the Netherlands. Neth Heart J 2015; 23: 161-5.